| | | | |
CUSIP No. 43157M102 | | Schedule 13G | | Page 11 of 16 |
ITEM 1. | (a) Name of Issuer: |
HilleVax, Inc. (the “Issuer”).
| (b) | Address of Issuer’s Principal Executive Offices: |
75 State Street, Suite 100 - #9995, Boston, MA 02109
ITEM 2. | (a) Name of Person Filing: |
Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:
The Carlyle Group Inc.
Carlyle Holdings I GP Inc.
Carlyle Holdings I GP Sub L.L.C.
Carlyle Holdings I L.P.
CG Subsidiary Holdings L.L.C.
TC Group, L.L.C.
Carlyle Investment Management L.L.C.
Carlyle Genesis UK LLC
Abingworth LLP
Abingworth Bioventures 8 LP
| (b) | Address or Principal Business Office: |
The principal business address of each of Abingworth LLP and Abingworth Bioventures 8 LP is 38 Jermyn Street, London, SW1Y 6DN, England, United Kingdom. The principal business address of each of the other Reporting Persons is c/o The Carlyle Group, 1001 Pennsylvania Ave. NW, Suite 220 South, Washington, DC 20004-2505.
| (c) | Citizenship of each Reporting Person is: |
Each of Abingworth LLP and Abingworth Bioventures 8 LP is organized under the laws of England and Wales. Each of the other Reporting Persons is organized under the laws of the State of Delaware.
| (d) | Title of Class of Securities: |
Common Stock, par value $0.0001 per share (“Common Stock”).
43157M102